Abstract: A display device including a display panel including a display area including emission areas and a non-emission area adjacent to the emission areas, wherein the display panel includes: a pixel defining layer that includes first openings corresponding to the emission areas and a second opening corresponding to the non-emission area; light emitting elements each including a first electrode, a second electrode, and a light emitting layer disposed between the first electrode and the second electrode, wherein each of the light emitting elements is disposed in a corresponding one of the first openings; and a photovoltaic element including a first cell electrode, a second cell electrode, and an optical photovoltaic layer disposed between the first cell electrode and the second cell electrode, wherein the photovoltaic element is disposed in the second opening.

Abstract: A display device includes a substrate including an emission area and a non-emission area, alignment electrodes arranged to be spaced from each other in a first direction on the substrate and extending in a second direction crossing the first direction, and pixels arranged along the second direction. Pixels adjacent to each other in the second direction from among the pixels may be configured to emit light of different colors. Each of the pixels may include first light emitting elements on the alignment electrodes and arranged along the second direction, second light emitting elements on the alignment electrodes, spaced from the first light emitting elements in the first direction, and arranged along the second direction, a first pixel electrode electrically connected to a first driving power and first ends of the first light emitting elements, a second pixel electrode spaced from the first pixel electrode in the first direction.

Abstract: The present invention relates to a method for producing astrocytes comprising obtaining neural progenitor cells from stem cells so as to continuously produce astrocytes with high purity and same traits, followed by two steps of differentiating the neural progenitor cells into the astrocytes, and astrocytes produced therefrom. Since the method of preparing the astrocytes provided in the present invention enables not only production of the astrocytes with high purity and faster production of the astrocytes with same characteristics, but also rapid differentiation of the astrocytes using the neural progenitor cells when necessary, it can be widely used for effectively treating a patient with a disease which requires transplantation of the astrocytes.

Abstract: The present invention relates to a method for producing cholinergic neurons comprising obtaining neural progenitor cells from stem cells so as to continuously produce cholinergic neural cells with high purity and the same traits, followed by differentiating the neural progenitor cells into the cholinergic neurons, and cholinergic neurons produced therefrom. Since the method of preparing the cholinergic neurons provided in the present invention enables not only production of the cholinergic neurons with high purity, but also rapid production of the cholinergic neurons with the same traits, it can be widely used for effectively treating degenerative cranial nerve diseases such as Alzheimer's disease.

Abstract: The present invention relates to a method for producing astrocytes comprising obtaining neural progenitor cells from stem cells so as to continuously produce astrocytes with high purity and same traits, followed by two steps of differentiating the neural progenitor cells into the astrocytes, and astrocytes produced therefrom. Since the method of preparing the astrocytes provided in the present invention enables not only production of the astrocytes with high purity and faster production of the astrocytes with same characteristics, but also rapid differentiation of the astrocytes using the neural progenitor cells when necessary, it can be widely used for effectively treating a patient with a disease which requires transplantation of the astrocytes.

Abstract: The present invention relates to a method for producing cholinergic neurons comprising obtaining neural progenitor cells from stem cells so as to continuously produce cholinergic neural cells with high purity and the same traits, followed by differentiating the neural progenitor cells into the cholinergic neurons, and cholinergic neurons produced therefrom. Since the method of preparing the cholinergic neurons provided in the present invention enables not only production of the cholinergic neurons with high purity, but also rapid production of the cholinergic neurons with the same traits, it can be widely used for effectively treating degenerative cranial nerve diseases such as Alzheimer's disease.

Abstract: The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.

Abstract: The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.

Abstract: Methods and apparatuses for reducing an erroneous color effect in a field-sequential liquid crystal display (FSLCD) are disclosed. An apparatus for reducing the erroneous color effect may include a data response time compensation (RTC) block which uses an RTC lookup table to provide a fast transition response time from one gray level to another gray level for a liquid crystal pixel cell by using a response time compensation (RTC) scheme during a color LED backlighting sequence. The apparatus may also include a VCOM and Gamma reference control block to generate a voltage boost and provide boost control to the liquid crystal pixel cell in a FSLCD panel, wherein the voltage boost gives a fast gray level transition to remove residual color caused by a slow transition time between liquid crystal light transmittance levels for the liquid crystal pixel cell.

Abstract: Disclosed are libraries of chimeric zinc finger domains. The libraries can include two or more zinc finger domains from naturally occurring proteins, e.g., mammalian proteins and particularly human proteins. Useful chimeric zinc finger domains can be identified from the library. Also disclosed are the amino acid sequences of zinc finger domains that recognize particular sites.

Abstract: Disclosed are libraries of chimeric zinc finger domains. The libraries can include two or more zinc finger domains from naturally occurring proteins, e.g., mammalian proteins and particularly human proteins. Useful chimeric zinc finger domains can be identified from the library. Also disclosed are the amino acid sequences of zinc finger domains that recognize particular sites.